Companies › EpiDestiny
1 active drug program in 105 registered trials: 55 Phase 2, 46 Phase 1, 2 Phase 4, 2 Phase 3; Neurology, Hematology, Oncology, Other; next expected readout Oct 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Decitabine DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor | DNMT3A, DNMT1 | Phase 1 | Sickle Cell Disease; Multiple Sclerosis; Allogeneic Hematopoietic Stem Cell Transplantation (HSCT); AML (Acute Myeloid Leukemia) … | Oct 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04476199 | Decitabine | Phase 2 | Acute Myeloid Leukemia | Oncology | Feb 2023 |
| NCT04763928 | Decitabine | Phase 2 | Acute Myeloid Leukemia | Oncology | Oct 2024 |
| NCT04905810 | Decitabine | Phase 2 | Acute Myeloid Leukemia | Oncology | May 2025 |
| NCT04817241 | Decitabine | Phase 1 | Acute Myeloid Leukemia | Oncology | Jun 2025 |
| NCT03240211 | Decitabine | Phase 1 | PTCL | Oncology | Jul 2025 |
| NCT05870995 | Decitabine | Phase 2 | Refractory Leukemia | Oncology | Feb 2026 |
| NCT06683885 | Decitabine | Phase 1 | Newly Diagnosed Diffuse Large B-cell Lymphoma | Oncology | May 2026 |
| NCT02961101 | Decitabine | Phase 1 | Malignancies Multiple | Oncology | May 2026 |
| NCT05089370 | Decitabine | Phase 1 | Malignant Melanoma | Oncology | Aug 2026 |
| NCT05657639 | Decitabine | Phase 2 | Acute Myeloid Leukemia | Oncology | Oct 2026 |
| NCT04097470 | Decitabine | Phase 2 | AML/MDS | Oncology | Nov 2026 |
| NCT04980404 | Decitabine | Phase 1 | Myelodysplastic Syndromes | Oncology | Nov 2026 |
| NCT06454448 | Decitabine | Phase 1 | Adebrelimab (SHR-1316) | Oncology | Nov 2026 |
| NCT07712848 | Decitabine | Phase 3 | AML (Acute Myeloid Leukemia) | Oncology | Dec 2026 |
| NCT06701357 | Decitabine | Phase 2 | DLBCL | Oncology | Dec 2026 |
| NCT04178005 | Decitabine | Phase 4 | Multiple Sclerosis | Neurology | Dec 2026 |
| NCT07044544 | Decitabine | Phase 1 | Myeloid Malignancy | Oncology | Dec 2026 |
| NCT05603884 | Decitabine | Phase 2 | Leukemia, Myeloid, Acute | Oncology | Dec 2026 |
| NCT06060782 | Decitabine | Phase 1 | Burkitt Lymphoma | Oncology | Dec 2026 |
| NCT05010772 | Decitabine | Phase 1 | Acute Myeloid Leukemia | Oncology | Dec 2026 |
| NCT06651866 | Decitabine | Phase 1 | Acute Myeloid Leukemia | Oncology | Dec 2026 |
| NCT05455294 | Decitabine | Phase 1 | Myeloid Malignancy | Oncology | Dec 2026 |
| NCT06401603 | Decitabine | Phase 1 | Advanced Chronic Myeloid Leukemia | Oncology | Jan 2027 |
| NCT04340843 | Decitabine | Phase 2 | Locally Advanced Unresectable Primary Central Chondrosarcoma | Oncology | Jan 2027 |
| NCT05038592 | Decitabine | Phase 1 | Chronic Myelomonocytic Leukemia | Oncology | Jan 2027 |
| NCT01627041 | Decitabine | Phase 2 | Acute Myeloid Leukemia | Oncology | Feb 2027 |
| NCT05396859 | Decitabine | Phase 1 | Acute Myeloid Leukemia | Oncology | Feb 2027 |
| NCT00095784 | Decitabine | Phase 2 | Primary Myelofibrosis | Oncology | Feb 2027 |
| NCT04375631 | Decitabine | Phase 1 | Recurrent Acute Myeloid Leukemia | Oncology | Feb 2027 |
| NCT03875287 | Decitabine | Phase 1 | Solid Tumor | Oncology | Mar 2027 |
| NCT05222984 | Decitabine | Phase 1 | Recurrent Acute Myeloid Leukemia | Oncology | Mar 2027 |
| NCT06156579 | Decitabine | Phase 2 | AML | Oncology | Mar 2027 |
| NCT05184842 | Decitabine | Phase 2 | Myelodysplastic Syndromes | Oncology | Mar 2027 |
| NCT06327685 | Decitabine | Phase 1 | Systemic Mastocytosis With an Associated Hematologic Neoplasm | Oncology | Mar 2027 |
| NCT06327685 | Decitabine | Phase 1 | Systemic Mastocytosis With an Associated Hematologic Neoplasm | Oncology | Mar 2027 |
| NCT06129734 | Decitabine | Phase 1 | Myeloid Malignancy | Oncology | Mar 2027 |
| NCT01861314 | Decitabine | Phase 1 | Acute Myeloid Leukemia | Oncology | Mar 2027 |
| NCT02957968 | Decitabine | Phase 2 | Breast Adenocarcinoma | Oncology | Mar 2027 |
| NCT07012044 | Decitabine | Phase 1 | Acute Myeloid Leukemia Post Cytotoxic Therapy | Oncology | Mar 2027 |
| NCT06393985 | Decitabine | Phase 2 | B-cell Acute Lymphoblastic Leukemia | Oncology | Apr 2027 |
| NCT03586609 | Decitabine | Phase 2 | Acute Myeloid Leukemia | Oncology | Apr 2027 |
| NCT04975919 | Decitabine | Phase 2 | Recurrent Acute Biphenotypic Leukemia | Oncology | May 2027 |
| NCT06393361 | Decitabine | Phase 2 | Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma | Oncology | Jun 2027 |
| NCT03164057 | Decitabine | Phase 2 | Acute Myeloid Leukemia | Oncology | Jun 2027 |
| NCT05272384 | Decitabine | Phase 1 | Recurrent B-Cell Non-Hodgkin Lymphoma | Oncology | Jun 2027 |
| NCT00412594 | Decitabine | Phase 2 | Hairy Cell Leukemia | Oncology | Jun 2027 |
| NCT06827899 | Decitabine | Phase 2 | Acute Myeloid Leukemia | Oncology | Jun 2027 |
| NCT05961644 | Decitabine | Phase 2 | Multiple Sclerosis, Secondary Progressive | Neurology | Jun 2027 |
| NCT06445959 | Decitabine | Phase 1 | Mutant IDH1 Inhibitor Olutasidenib | Other | Jun 2027 |
| NCT06445959 | Decitabine | Phase 1 | Mutant IDH1 Inhibitor Olutasidenib | Other | Jun 2027 |
| NCT03041688 | Decitabine | Phase 1 | Acute Myeloid Leukemia | Oncology | Jun 2027 |
| NCT07172204 | Decitabine | Phase 2 | Intensive Chemotherapy Unfit | Oncology | Jul 2027 |
| NCT06536959 | Decitabine | Phase 2 | Relapsed Acute Myeloid Leukemia | Oncology | Jul 2027 |
| NCT06532552 | Decitabine | Phase 2 | Acute Myeloid Leukemia, Adult | Oncology | Aug 2027 |
| NCT02890329 | Decitabine | Phase 1 | Previously Treated Myelodysplastic Syndrome | Oncology | Aug 2027 |
| NCT05600894 | Decitabine | Phase 2 | Chronic Myelomonocytic Leukemia | Oncology | Aug 2027 |
| NCT06712121 | Decitabine | Phase 2 | T Lymphoblastic Leukemia/Lymphoma | Oncology | Aug 2027 |
| NCT06511882 | Decitabine | Phase 2 | Acute Myeloid Leukemia | Oncology | Oct 2027 |
| NCT06232655 | Decitabine | Phase 2 | Acute Myeloid Leukemia | Oncology | Oct 2027 |
| NCT06923488 | Decitabine | Phase 1 | Myelodysplastic Syndromes | Hematology | Oct 2027 |
The 60 nearest readouts of 105 trials; the rest in the app.
Taiho Oncology AbbVie Bristol-Myers Squibb Otsuka Taiho Pharmaceutical
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.